Hella Kohlhof at 4SC AG to Speak at 2nd Cancer Epigenetics Conference Nov 8-9, 2012 Boston, MA
Hella Kohlhof, Manager of Translational Pharmacology at 4SC AG will give a presentation on "4SC-202: A Novel Epigenetic Modulator to Target Cancer Stem Cells"
- San Diego, CA (1888PressRelease) September 24, 2012 - Hella Kohlhof, Manager of Translational Pharmacology at 4SC AG will give a presentation on "4SC-202: A Novel Epigenetic Modulator to Target Cancer Stem Cells" at the 2nd Cancer Epigenetics conference taking place on Nov 8-9, 2012 in Boston, MA.
4SC-202 is an oral HDAC inhibitor with a unique combination of anti-cancer mode of actions, namely epigenetic regulation, proliferation inhibition and targeting of stemness. 4SC-202 treatment leads to very distinct histone modifications and inhibition of protein deacetylation. Analysis of gene expression suggests unique features of 4SC-202 compared to other class I specific HDAC inhibitors. Currently, 4SC-202 is tested in a phase I clinical trial (TOPAS) in hematological indications to investigate safety, tolerability and pharmacokinetics as primary objective. As secondary objective several PD/biomarker readouts are evaluated including ex vivo assays to determine the extent of HDAC inhibition in PBMCs and protein acetylation and regulation of gene expression.
Hella Kohlhof studied Biology in Aachen and Munich and received her Ph.D. from the Ludwig Maximilians University in Munich, Germany. During her Ph.D. and PostDoc position she worked on the Notch Signaling Pathway at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich. In 2008 she joined 4SC Company as a Research Scientist and Group Leader of the oncology research laboratory. She is responsible for establishment and supervision of biological assays necessary for mode of action and cellular toxicity studies for all 4SC's oncological projects including HDAC and kinase inhibitors. Since June 2011, she is also responsible for the management of 4SC's histone deacetylase inhibitor (HDI) development project (4SC-202) in hemato-oncologic indications.
GTC's 2nd Cancer Epigenetics conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, is the only cancer epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam